YOLFTbeta
Aurisco Pharmaceutical Co Ltd

Aurisco Pharmaceutical Co Ltd

605116 · SHG · Healthcare / Biotechnology

17.78CNY-0.22 (-1.22%)

Price History

Full chart

Market Stats

Previous Close18.00
Open18.00
Day Range17.59 – 18.02
52-Week Range17.79 – 34.98
Volume1.95M
Market Cap8.15B
P/E (TTM)22.05
Forward P/E0.00
EPS0.91
Dividend Yield1.69%
Beta-0.35
50-Day Avg19.90
200-Day Avg23.28

About

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides eplerenone, an API to treat cardiovascular diseases, lowering blood pressure, and treating heart failure; futicasone propionate, used for the treatment of asthma, respiratory tract diseases, and rhinitis; Tenofovir, an anti-infection used to treat AIDS and hepatitis B; pregabalin for the treatment of anti-epileptic, analgesic, and anti-anxiety purposes, as well as for neuralgia; abiraterone acetate to treat prostate cancer; and dydrogesterone, to treat endogenous for women's heath. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Dingjun Chu
  • Employees2.03K
  • HeadquartersBadu Industrial Park Zone, Tiantai, China, 317200, China
  • Websitehttps://www.aurisco.com

Leadership

  • Mr. Dingjun ChuGM & Director · b. 1973
  • Ms. Xiuyu WangDeputy GM, Accounting Supervisor & Financial Director · b. 1981
  • Ms. Liqin ZhangDeputy GM & Director of Sales · b. 1976
  • Mr. Guoping WangDeputy GM & Director · b. 1966
  • Ms. Fangfang LiBoard Secretary · b. 1972
  • Mr. Zhenping ZhaoDeputy General Manager · b. 1973
  • Ms. Mingyan XinDeputy General Manager · b. 1969
  • Mr. Jieming ChenDeputy General Manager · b. 1974

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue590.42M544.40M575.41M581.63M721.44M803.36M1.01B1.26B1.48B1.70B
Growth (%)--7.79%+5.70%+1.08%+24.04%+11.36%+25.48%+25.24%+16.89%+15.03%
Cost of Revenue285.39M280.26M303.15M284.01M381.12M408.64M495.51M564.22M631.38M684.64M
Gross Profit305.03M264.15M272.27M297.63M340.32M394.72M512.57M698.32M844.36M1.01B
Gross Margin51.66%48.52%47.32%51.17%47.17%49.13%50.85%55.31%57.22%59.67%
Operating Expense193.24M194.09M107.61M126.92M153.05M201.10M271.29M367.59M433.86M453.46M
Operating Income111.79M70.05M164.66M170.71M187.27M193.62M241.28M330.73M410.50M559.38M
Operating Margin18.93%12.87%28.62%29.35%25.96%24.10%23.93%26.20%27.82%32.95%
EBITDA119.34M77.92M171.92M234.76M218.29M244.65M307.35M406.88M505.55M678.98M
EBITDA Margin20.21%14.31%29.88%40.36%30.26%30.45%30.49%32.23%34.26%40.00%
Net Income86.70M44.72M136.83M186.13M157.23M168.71M210.96M289.42M354.79M449.21M
Net Income Margin14.69%8.21%23.78%32.00%21.79%21.00%20.93%22.92%24.04%26.46%
R&D17.90M23.53M24.65M35.10M47.35M69.35M117.26M136.89M146.34M153.39M
R&D as % of Total Revenue3.03%4.32%4.28%6.03%6.56%8.63%11.63%10.84%9.92%9.04%
Interest Expense13.78M1.93M584.96K545.96K529.62K1.17M1.66M3.65M16.80M34.71M
Interest Expense % of Total Revenue2.33%0.35%0.10%0.09%0.07%0.15%0.16%0.29%1.14%2.04%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets781.82M816.38M920.70M1.10B1.53B1.72B2.03B2.57B3.88B4.22B
Total Liabilities192.01M132.44M133.16M122.96M147.98M213.44M348.68M607.03M1.55B1.56B
Total Equity552.08M683.95M787.54M977.28M1.39B1.51B1.68B1.97B2.33B2.66B
Cash183.57M212.89M180.72M265.06M564.10M444.61M391.74M545.84M769.44M792.37M
Total Debt48.00M21.00M9.06M6.77M12.59M17.97M52.69M116.88M942.21M-
Net Debt-135.57M-191.89M-171.66M-258.29M-551.51M-426.64M-339.05M-428.95M172.77M145.60M

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow188.30M117.91M109.77M179.90M214.48M201.57M166.41M385.61M332.41M421.50M
Investing Cash Flow-48.82M-145.97M-75.96M-82.10M-157.01M-262.34M-256.79M-365.27M-726.77M-
Financing Cash Flow-54.55M54.66M-57.04M759.79K246.94M-52.49M-14.91M49.02M734.37M-
Capital Expenditure53.68M106.60M94.14M72.47M158.80M250.61M216.23M305.48M540.28M350.07M
Free Cash Flow134.62M11.31M15.63M107.43M55.68M-49.04M-49.82M80.13M-207.87M71.42M
Dividends Paid75.98M58.44M36.04M-36.00M48.12M52.13M64.99M94.82M124.12M
FCF to OCF71.49%9.59%14.23%59.72%25.96%-24.33%-29.94%20.78%-62.54%16.95%
Dividend Paid to FCF56.44%516.73%230.63%-64.65%-98.12%-104.64%81.11%-45.61%173.78%

Earnings

Report DateSep 30, 2020Dec 31, 2020Apr 28, 2021Aug 30, 2021Oct 29, 2021Dec 31, 2021Apr 29, 2022Aug 26, 2022Oct 30, 2022Dec 31, 2022Apr 28, 2023
EPS Estimate-----------
EPS Actual0.090.040.080.130.130.090.100.190.170.060.06
Surprise-----------
Timing--Pre-marketAfter-hoursPre-market-Pre-marketPre-marketAfter-hours-Pre-market

Key Statistics & Ratios

Market Cap8.15B
Enterprise Value8.36B
Trailing P/E22.05
Forward P/E0.00
Price / Sales4.78
Price / Book3.03
EPS0.91
Book Value6.46
Revenue (TTM)1.70B
Gross Profit (TTM)960.47M
EBITDA639.07M
Profit Margin21.89%
Operating Margin29.59%
Return on Equity14.62%
Return on Assets7.49%
Shares Outstanding406.18M
Shares Float93.84M
Beta-0.35
Dividend Yield1.69%
Dividend Rate0.34
Payout Ratio37.36%

Dividends

20261×
0.34Jun 15, 2026
20251×
0.29Jun 20, 2025
20241×
0.22Jun 6, 2024
20231×
0.16May 22, 2023
20221×
0.13Jun 6, 2022
20211×
0.12Jun 1, 2021